Current News - U.S.
- Boehringer Ingelheim Committed to Advancing the Science of Hypoactive Sexual Desire Disorder
- Second Chances Study Shows Most Stroke Survivors “Very Satisfied” with their Overall Quality of Life
- Landmark ONTARGET™ trial demonstrates Micardis® is equally effective as ramipril, with fewer discontinuations, in a broad high-risk cardiovascular population
-
Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA
“Seal Of Approval” - Boehringer Ingelheim announces enrollment is complete for the largest atrial fibrillation outcomes trial – The RE-LY™ Study
- Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune® (nevirapine) to a Ritonavir-Boosted Atazanavir–based Regimen in Treatment-Naïve HIV Patients
- View more Current News : : View the News Archive
BI Spotlight
Second Chances Study Shows Most Stroke Survivors “Very Satisfied” with their Overall Quality of Life
Chicago, IL - April 29, 2008 --
Patients who have survived a stroke report surprisingly high overall life satisfaction, according to the preliminary results of the Second Chances™ study.
Product Sites
Job Openings
Our Locations
R&D
